IFF outlines a path for Scent’s recovery driven by a rebuilt R&D engine, an enhanced pipeline, and stronger go-to-market execution. In 2H 2026, Fine Fragrance is expected to soften in Q3 before a stronger Q4 with mid-single-digit growth, while Consumer Fragrance trends toward a low single-digit rate; Fragrance Ingredients momentum supports near-term results as R&D plans build toward 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management describes a turnaround in Scent’s innovation engine: they state that about 2.5 years ago the R&D pipeline “was not what it should have been,” but that today they have a “very strong R&D capability,” a strong R&D team, great perfumers, and a “great pipeline of molecules as well as delivery systems.” 1 This improvement is framed as enabling the creation of leading-edge new Fine Fragrances and Consumer Fragrances. 1
Along with the pipeline, management highlights rebuilding the R&D capability and the “go-to-market approach with customers” as part of how Scent supports market share gains. 2 This is explicitly tied to the Consumer Fragrance recovery story (rebuilding R&D capability + customer approach to drive share). 2
Fine Fragrance is described as facing “noise due to the Middle East conflict” with management noting they managed the challenges in the Middle East such that Fine Fragrance finished slightly positive vs. an expected mid-single-digit decline. 34 Management also explains the sequencing: factor a softer Q3 due in part to a ~20% year-over-year comp in Q3 of the prior year, and then “start to see some recovery as we get to Q4.” 4
In the near term, a key driver of Scent’s Q2 performance was Fragrance Ingredients growth “north of 20%,” supported by leveraging the synthetics portfolio to capture more sales during macro/supply chain disruption conditions and higher Brent crude prices. 4 Management adds that as conditions settle, they expect normalization—specifically a shift back toward higher value-added ingredients vs. traditional synthetics—and notes this normalization is forecast for the second half. 4
At the segment level, Scent delivered $665 million of sales (+8%) and EBITDA of $134 million (+5%), with management attributing profitability gains primarily to volume growth and productivity gains. 5 This matters because recovery is not only about demand—it’s also about execution and productivity. 5
Management lays out the second-half trajectory this way:
They also reiterate that the team is managing Middle East uncertainty/volatility, with Q2 slightly positive despite the expected down trend going into the quarter. 4
Management’s second-half view for Consumer Fragrance is:
Even though your question is focused on Fine vs. Consumer Fragrance, Scent results are also influenced by the Fragrance Ingredients piece (part of Scent reporting):
Based on the excerpts, the R&D plan is less presented as a formal multi-year budget and more as a capability/pipeline strategy with milestones and directional targets:
Management’s retrospective framing is explicit: the company recognized that the R&D pipeline was behind target 2.5 years ago, and since then has built:
This is the foundation to support 2027, because it targets both “molecule” innovation and the delivery systems needed to convert new ingredients into customer-ready products. 1
Management ties the recovery and market share gains not only to having R&D capability, but also to rebuilding R&D capability and the go-to-market approach with customers. 2 That indicates the 2027 support plan includes commercialization readiness—not just lab progress. 2
Management draws a timing line for competitive positioning: a shift to higher-value natural products is underway and will take more time; they say it will not be in the second half of this year, but as we go into next year and the year after they believe they’ll have a strong competitive position. 2 Since the question asks about support for 2027, this “year after next” language is consistent with preparing the substrate (portfolio and ingredient mix) for later multi-year performance improvements. 2
Management also situates innovation in a transformation/investment thesis: they emphasize a continued need to reinvest in innovation because it is part of a “circle” where investments improve growth and, ultimately, margins. 6 While this excerpt discusses the broader Remainco portfolio, it supports the idea that R&D is an ongoing strategic pillar rather than a one-off fix. 6
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent rebound hinges on stabilizing Fine Fragrance amid Middle East volatility, with Q3 softness and Q4 rebound, while Consumer Fragrance recovery relies on rebuilt R&D go-to-market capabilities and market-share gains. Fragrance Ingredients provide momentum that is expected to normalize in 2H, underpinning a stronger 2027 pipeline and competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by rebuilding R&D and go-to-market engines, plus a strategic shift toward higher-value natural ingredients, while navigating Middle East volatility. In 2H 2026, Fine Fragrance is projected softer in Q3 and stronger in Q4, and Consumer Fragrance should normalize to a low single-digit growth. The 2027 plan hinges on perfumer-led innovation, robust pipelines, and new delivery systems to win market share.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi-year Scent recovery driven by stronger R&D, a rebuilt pipeline, and market-share gains, with near-term normalization across Fine Fragrance and Consumer Fragrance. In H2, Fine Fragrance is expected to improve toward a Q4 rebound, Consumer Fragrance normalizes to low single-digit growth, and sustained R&D investment is aimed at strengthening competitiveness into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management outlines a disciplined capex path for Remainco, signaling capex around 5–6% of sales and R&D around 8–9% as a post-divestiture growth engine. They stress reinvestment to fuel innovation, margin expansion, and ongoing value creation, while noting near-term headwinds from the stand-alone transition.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Following the divestiture, IFF outlined a disciplined capex plan of 5-6% (tilting toward 6% over the next 1-2 years) and a sustained reinvestment cycle focused on R&D to differentiate the Remainco portfolio. The company also signaled stronger cash generation, projected deleveraging with net proceeds, and strategic cost management to support growth and margin expansion.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi